Vesicles

Codiak Presents Preclinical Data at SITC 2020 Demonstrating Potential of engEx™ Engineered Exosomes to Stimulate Targeted, Integrated Anti-Tumor Immunity

Retrieved on: 
Monday, November 9, 2020
Branches of biology, RNA, Exosome, Vesicles

The company initiated clinical trials in September 2020 for two engineered exosome candidates, exoIL-12 and exoSTING, for the treatment of lymphoid and solid tumors.

Key Points: 
  • The company initiated clinical trials in September 2020 for two engineered exosome candidates, exoIL-12 and exoSTING, for the treatment of lymphoid and solid tumors.
  • exoIL-12 is a novel exosome therapeutic candidate engineered to display active IL-12 on the surface of the exosome.
  • The current studies extend observations from previous presentations demonstrating tumor retention and increased tumor growth inhibition across multiple mouse models.
  • Highlights from the data presented at SITC 2020 include:
    exoIL-12 was ~100 fold more potent in tumor growth inhibition than rIL-12.

Capricor Therapeutics to Present Third Quarter 2020 Financial Results and Recent Corporate Update on November 12

Retrieved on: 
Thursday, November 5, 2020
Branches of biology, Vesicles, Exosome, Forward-looking statement, Extracellular vesicle

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases.

Key Points: 
  • Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases.
  • Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders.
  • There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements.
  • All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, October 28, 2020
Exosome, Vesicles, Medical device

SAN DIEGO, Oct. 28, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its second quarter ended September 30, 2020 and provided an update on recent developments.

Key Points: 
  • SAN DIEGO, Oct. 28, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its second quarter ended September 30, 2020 and provided an update on recent developments.
  • Aethlon Medical, Inc. (Company or Aethlon) is continuing the development of its proprietary Hemopurifier, which is a first in class therapeutic device designed for the single use depletion of cancer-promoting exosomes and circulating viruses.
  • Financial Results for the Second Quarter Ended September 30, 2020
    At September 30, 2020, we had a cash balance of approximately $14.5 million.
  • The Company will hold a conference call today, Wednesday, October 28, 2020 at 4:30 p.m. Eastern Time to review financial results and recent corporate developments.

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Pancreatic Cancer Abstract at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Thursday, October 15, 2020
Life sciences, Biology, Branches of biology, Biotechnology, Vesicles, Organelles, Lysosome, Biopharmaceutical

RBD selectively accumulates in the lysosomes of cancer cells upon contact, disrupts these lysosomes, and causes the cells to die.

Key Points: 
  • RBD selectively accumulates in the lysosomes of cancer cells upon contact, disrupts these lysosomes, and causes the cells to die.
  • The Company manufactures cGMP RBD using a patented process designed to meet stringent modern global quality requirements for pharmaceuticals and pharmaceutical ingredients.
  • RBD selectively accumulates in the lysosomes of cancer cells upon contact, disrupting the lysosomes and causing the cells to die.
  • Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on an entirely- and wholly-owned family of small molecules called halogenated xanthenes.

Evox Therapeutics appoints Dr David Lowe as Vice President of Research

Retrieved on: 
Tuesday, October 13, 2020
Branches of biology, Biology, Exosome, Vesicles, Messenger RNA

OXFORD, England, Oct. 13, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce the appointment of Dr David Lowe as Vice President (VP) of Research.

Key Points: 
  • OXFORD, England, Oct. 13, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce the appointment of Dr David Lowe as Vice President (VP) of Research.
  • David will be overseeing the 40-person Research group with a view to advancing Evox's pipeline as well as continuing the development of the Company's proprietary exosome platform.
  • David has over 20 years of biotech and large pharma R&D experience in advancing protein and antibody-based therapeutics as well as exploring novel therapeutic modalities such as gene therapy, mRNA therapeutics and exosomes.
  • Dr Antonin de Fougerolles, Chief Executive Officer of Evox, commented:
    "The appointment of David represents another important hire for Evox Therapeutics as we expand the scope of our research activities and translate those advances into impactful drugs for patients.

Global Exosomes Pipeline Insight Report 2020: Insights on 50+ Companies and 50+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, October 9, 2020
Health, Pharmaceutical, Vesicles, Exosome, Branches of biology, Pipeline, Insulin-degrading enzyme

The Exosomes - Pipeline Insight, 2020 report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Exosomes pipeline landscape.

Key Points: 
  • The Exosomes - Pipeline Insight, 2020 report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Exosomes pipeline landscape.
  • This segment of the Exosomes report encloses its detailed analysis of various drugs in the different stages of clinical development, including phase II, I, preclinical and Discovery.
  • This segment of the report provides insights about the different Exosomes based drugs segregated based on the following parameters that define the scope of the report, such as:
    There are approx.
  • Exosomes pipeline report provides the rapeutic assessment of the pipeline drugs by the Route of Administration.

Aegle Therapeutics Completes $6.5M Series A Financing

Retrieved on: 
Tuesday, September 29, 2020
Branches of biology, Genodermatoses, Vesicles, Rare diseases, Collagen disease, Epidermolysis bullosa dystrophica, Epidermolysis bullosa, Exosome, Aegle, Extracellular vesicle, Deb

BOSTON and MIAMI, Sept. 29, 2020 /PRNewswire/ --Aegle Therapeutics Corporation, a first-in-class biotechnology company developing extracellular vesicles as therapy, today announced the completion of a $6.5M Series A round of financing.

Key Points: 
  • BOSTON and MIAMI, Sept. 29, 2020 /PRNewswire/ --Aegle Therapeutics Corporation, a first-in-class biotechnology company developing extracellular vesicles as therapy, today announced the completion of a $6.5M Series A round of financing.
  • Aegle's groundbreaking therapy is initially being developed to treat dystrophic epidermolysis bullosa ("DEB"), a rare pediatric skin blistering disorder.
  • Lonnie Moulder, founding partner of Tellus BioVentures, said, "We are excited to support Aegle Therapeutics at this critical juncture in the company's development.
  • Aegle Therapeutics ( www.aegletherapeutics.com ) is a privately held biotechnology company developing extracellular vesicles, including exosomes, secreted by mesenchymal stem cells as therapy for the treatment of dystrophic epidermolysis bullosa and other severe dermatological conditions.

Carmine Therapeutics named as one of FierceBiotech's "Fierce 15" Biotech Companies of 2020

Retrieved on: 
Monday, September 28, 2020
Branches of biology, Biology, Vesicles, Cell biology, Cells, Extracellular vesicle, Carmine

Carmine Therapeutics is pioneering a novel class of therapeutics based on its REGENT technology an innovative approach which leverages red blood cell extracellular vesicles (RBCEVs).

Key Points: 
  • Carmine Therapeutics is pioneering a novel class of therapeutics based on its REGENT technology an innovative approach which leverages red blood cell extracellular vesicles (RBCEVs).
  • In June 2020, Carmine Therapeutics signed a research collaboration agreement with Takeda Pharmaceutical Company Limited to discover, develop and commercialize transformative non-viral gene therapies.
  • Carmine Therapeutics will be eligible for over $900M USD in total milestone payments plus tiered royalties.
  • Headquartered in Cambridge, MA, Carmine is pioneering a new class of therapeutics based on red blood cell extracellular vesicles (RBCEVs).

LabRoots Announces Speakers to Present Cutting-Edge Research Findings at its 4th Annual Cell Biology Virtual Conference

Retrieved on: 
Thursday, September 17, 2020
Branches of biology, Biology, Cell biology, Vesicles, Cellular processes, Exosome, Endocytosis, Organelle, Labroots

YORBA LINDA, Calif., Sept. 17, 2020 /PRNewswire-PRWeb/ -- LabRoots , the leading scientific social networking website offering premier, interactive virtual events and webinars, will be hosting its Cell Biology Virtual Event , scheduled on September 23, 2020.

Key Points: 
  • YORBA LINDA, Calif., Sept. 17, 2020 /PRNewswire-PRWeb/ -- LabRoots , the leading scientific social networking website offering premier, interactive virtual events and webinars, will be hosting its Cell Biology Virtual Event , scheduled on September 23, 2020.
  • This day-long forum marks the fourth annual event that will attract innovative researchers, top scientists, biologists, and leading academia and industry from across the globe.
  • Emphasizing the principals and fundamentals of biology, the one-day program features four sessions encompassing Organelle Dynamics, Cell Biology of Cancer, Extra Cellular Matrices, and Exosomes convening global leaders to present their latest progress in cell research.
  • of Biochemistry and Molecular Biology, Director, UNMC Advanced Microscopy Core Facility on sorting out the mechanisms of endocytic recycling.

Codiak Initiates Subject Dosing in a Phase 1 Clinical Trial of exoIL-12™ for the Treatment of Cancer

Retrieved on: 
Tuesday, September 15, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Health, Branches of biology, Medicine, Vesicles, Exosome, Clinical research, Pharmaceutical industry, Clinical trial, exoIL-12™, the engEx™ Platform, Codiak BioSciences

The trial is Codiaks first human clinical trial and the first of two clinical development programs Codiak expects to initiate in 2020.

Key Points: 
  • The trial is Codiaks first human clinical trial and the first of two clinical development programs Codiak expects to initiate in 2020.
  • Our engEx platform allows us to engineer exosomes to selectively deliver potent therapeutic payloads, such as IL-12, to potentially enhance the therapeutic index.
  • Codiak is initially focusing development of exoIL-12 on tumors that have previously shown clinical responses to IL-12 used as a monotherapy, such as CTCL.
  • Codiak intends to focus development of exoIL-12 on tumors that have, in previous clinical testing, shown clinical responses to IL-12 used as a monotherapy.